• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.

作者信息

Tan Shuguang, Liu Kefang, Chai Yan, Zhang Catherine W-H, Gao Shan, Gao George F, Qi Jianxun

机构信息

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.

National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China.

出版信息

Protein Cell. 2018 Jan;9(1):135-139. doi: 10.1007/s13238-017-0412-8.

DOI:10.1007/s13238-017-0412-8
PMID:28488247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5777972/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671b/5777972/28dc318fb8d4/13238_2017_412_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671b/5777972/3f065c44b167/13238_2017_412_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671b/5777972/28dc318fb8d4/13238_2017_412_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671b/5777972/3f065c44b167/13238_2017_412_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671b/5777972/28dc318fb8d4/13238_2017_412_Fig2_HTML.jpg

相似文献

1
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.治疗性单克隆抗体度伐利尤单抗独特的程序性死亡受体配体1（PD-L1）结合特性
Protein Cell. 2018 Jan;9(1):135-139. doi: 10.1007/s13238-017-0412-8.
2
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.抗程序性死亡配体1（PD-L1）单克隆抗体阿维鲁单抗用于肿瘤治疗的结构基础
Cell Res. 2017 Jan;27(1):151-153. doi: 10.1038/cr.2016.102. Epub 2016 Aug 30.
3
Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.解析 PD-1 与 PD-L1 结合的结构和能量基础：分子建模视角。
Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):576-588. doi: 10.1016/j.bbagen.2017.11.022. Epub 2017 Dec 2.
4
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).程序性死亡配体1（PD-L1）小分子靶向的结构基础
Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.
5
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.免疫检查点受体 PD-1 及其配体 PD-L1/PD-L2 的结构生物学。
Structure. 2017 Aug 1;25(8):1163-1174. doi: 10.1016/j.str.2017.06.011.
6
Anti-PD-L1 inhibitor durvalumab in bladder cancer.抗程序性死亡配体1（PD-L1）抑制剂度伐利尤单抗在膀胱癌中的应用
Lancet Oncol. 2016 Jul;17(7):e275. doi: 10.1016/S1470-2045(16)30242-X. Epub 2016 Jun 16.
7
Durvalumab in non-small-cell lung cancer patients: current developments.度伐利尤单抗在非小细胞肺癌患者中的应用：最新进展。
Future Oncol. 2018 Feb;14(3):205-222. doi: 10.2217/fon-2017-0373. Epub 2017 Nov 15.
8
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.人程序性死亡蛋白1（PD-1）及其配体PD-L1复合物的结构
Structure. 2015 Dec 1;23(12):2341-2348. doi: 10.1016/j.str.2015.09.010. Epub 2015 Oct 22.
9
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.基于不同免疫组化抗体的三阴性乳腺癌中PD-L1的表达
J Transl Med. 2016 Jun 10;14(1):173. doi: 10.1186/s12967-016-0925-6.
10
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.一项关于度伐鲁单抗（MEDI4736）联合或不联合曲美木单抗用于既往接受过治疗的晚期非小细胞肺癌患者的III期研究：ARCTIC研究的原理与方案设计。
Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17.

引用本文的文献

1
Phenotypic and targeted drug discovery in immune therapeutics: challenges, opportunities, and future directions.免疫治疗中的表型和靶向药物发现：挑战、机遇与未来方向。
RSC Adv. 2025 Aug 22;15(36):29937-29951. doi: 10.1039/d5ra03914b. eCollection 2025 Aug 18.
2
Using extension-based mRNA display to design antibody-like proteinogenic peptides for human PD-L1.利用基于延伸的mRNA展示技术设计针对人程序性死亡受体配体1（PD-L1）的类抗体蛋白质生成肽。
Protein Sci. 2025 Sep;34(9):e70268. doi: 10.1002/pro.70268.
3
Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.

本文引用的文献

1
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.眼见为实：抗 PD-1/PD-L1 单克隆抗体在检查点阻断肿瘤免疫治疗中的作用。
Signal Transduct Target Ther. 2016 Nov 25;1:16029. doi: 10.1038/sigtrans.2016.29. eCollection 2016.
2
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.一种用于免疫检查点阻断的新型程序性死亡受体配体1纳米抗体的结构基础
Cell Discov. 2017 Mar 7;3:17004. doi: 10.1038/celldisc.2017.4. eCollection 2017.
3
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
创新免疫疗法及其对胃腺癌的变革性影响：对该疾病的起源、流行病学、分类、诊断和治疗选择的全面综述
ACS Pharmacol Transl Sci. 2025 Apr 18;8(6):1438-1472. doi: 10.1021/acsptsci.4c00677. eCollection 2025 Jun 13.
4
Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.为非小细胞肺癌患者组织样本的体外程序性死亡受体配体1（PD-L1）诊断而开发的肌调节蛋白变体。
J Transl Med. 2025 Jun 13;23(1):655. doi: 10.1186/s12967-025-06699-6.
5
A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling.一种针对头颈部鳞状细胞癌（HNSCC）中程序性死亡配体1（PD-L1）和骨髓来源间充质干细胞的新型治疗方法在体外阻碍了促转移特征：阻断肿瘤-基质通讯和信号传导的前景
Cell Commun Signal. 2025 Feb 10;23(1):74. doi: 10.1186/s12964-025-02073-7.
6
PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.树突状细胞迁移所需的细胞内信号传导需要PD-L1与CD80的相互作用。
Sci Adv. 2025 Jan 31;11(5):eadt3044. doi: 10.1126/sciadv.adt3044. Epub 2025 Jan 29.
7
Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition.药物研发的进展：整合计算机辅助药物设计工具与药物再利用以抑制PD-1/PD-L1轴
RSC Adv. 2025 Jan 23;15(4):2298-2316. doi: 10.1039/d4ra08245a.
8
An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.基于计算机的 PD-1 和 PD-L1 结合位点偏好性研究及其在设计靶向癌症治疗抗体中的应用
PLoS One. 2024 Jul 25;19(7):e0304270. doi: 10.1371/journal.pone.0304270. eCollection 2024.
9
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.探索PD-1/PD-L1成像示踪剂领域：从挑战到机遇
Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.
10
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.靶向 CD47 和 PD-L1 的轻链驱动双特异性抗体的结构分析。
MAbs. 2024 Jan-Dec;16(1):2362432. doi: 10.1080/19420862.2024.2362432. Epub 2024 Jun 7.
PD-1 中的一个意想不到的 N 端环主导了 nivolumab 的结合。
Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.
4
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.一清二楚：通过两种癌症治疗性单克隆抗体可视化PD-1/PD-L1相互作用的干预机制。
Protein Cell. 2016 Dec;7(12):866-877. doi: 10.1007/s13238-016-0337-7. Epub 2016 Nov 4.
5
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.癌症免疫疗法中单克隆抗体阻断检查点的结构基础。
Nat Commun. 2016 Oct 31;7:13354. doi: 10.1038/ncomms13354.
6
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.抗程序性死亡配体1（PD-L1）单克隆抗体阿维鲁单抗用于肿瘤治疗的结构基础
Cell Res. 2017 Jan;27(1):151-153. doi: 10.1038/cr.2016.102. Epub 2016 Aug 30.
7
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.治疗性抗体帕博利珠单抗阻断PD-1介导的免疫抑制的结构基础。
Cell Res. 2017 Jan;27(1):147-150. doi: 10.1038/cr.2016.77. Epub 2016 Jun 21.
8
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).免疫逃避 PD-L1/PD-1 阻断：成功（或失败）的七个步骤。
Ann Oncol. 2016 Aug;27(8):1492-504. doi: 10.1093/annonc/mdw217. Epub 2016 May 20.
9
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).程序性死亡配体1（PD-L1）小分子靶向的结构基础
Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730.
10
The Basis of Oncoimmunology.肿瘤免疫学基础。
Cell. 2016 Mar 10;164(6):1233-1247. doi: 10.1016/j.cell.2016.01.049.